Reporting of Drug-Induced Myopathies Associated with the Combination of Statins and Daptomycin: A Disproportionality Analysis Using the US Food and Drug Administration Adverse Event Reporting System

Ejemplares similares

• Comment on "Drug–Drug Interaction of the Sodium Glucose Co-Transporter 2 Inhibitors with Statins and Myopathy: A Disproportionality Analysis Using Adverse Events Reporting Data"
  por: Kuss, Oliver, et al.
  Publicado: (2023)
• Assessment of Reye’s syndrome profile with data from the US Food and Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases using the disproportionality analysis
  por: Matsumoto, Kiyoka, et al.
  Publicado: (2020)
• Adverse events associated with molnupiravir: a real-world disproportionality analysis in food and drug administration adverse event reporting system
  por: Liang, Yankun, et al.
  Publicado: (2023)
• Drug-induced torsades de pointes: Disproportionality analysis of the United States Food and Drug Administration adverse event reporting system
  por: Wu, Ziyang, et al.
  Publicado: (2022)
• Remdesivir for COVID-19 and acute kidney injury: disproportionality analysis of data from the U.S. Food and Drug Administration Adverse Event Reporting System
  por: Li, Xiaotong, et al.
  Publicado: (2023)